Researchers discovered a class of potent antibodies that cross‑neutralize the Marburg virus and the related Ravn virus, reporting results in npj Viruses. The antibodies show broad activity against filoviruses in preclinical assays, suggesting potential for therapeutic development and improved outbreak preparedness. Teams used structural and neutralization assays to characterize binding epitopes and breadth. The antibodies create a candidate pool for accelerated therapeutic development and stockpiling strategies; translational steps will include optimization, safety testing, and manufacturing scale‑up to support emergency response pipelines.